the administration of interferon-beta1b and favipiravir in patients with covid-19 pneumonia

To assess the efficacy of interferon-beta1b (inf-beta1b) in combination with favipiravir in early treatment of patients with covd-19 pneumonia. this prospective non-controlled study was performed on admitted patients with moderate to severe covid-19 disease to amir-alam hospital. the diagnosis of covid-19 pneumonia was based on positive rt-pcr test from nasopharyngeal samples and typical spiral chest ct scan findings. at the time of this study, there was the shortage of efficient anti-covid drugs especially “remdesivir” due to sanction of iran. all the patients received subcutaneous ifn-beta1b plus favipiravir. the patients with severe infection received intravenous dexamethasone. those who underwent invasive or noninvasive mechanical ventilation, at the admission onset, were excluded from the study. one hundred and eighty-two patients with moderate to severe covid-19 pneumonia were included in this study. among182 patients, 90 cases had moderate and 92 had severe pneumonia. twenty-one cases with severe pneumonia and 14 cases with moderate pneumonia were transferred to icu to receive invasive or non-invasive mechanical ventilation. the mean duration of hospital ward admission and icu stay was 10.69±7.54 and 5.45±2.72 days, respectively. one hundred and seventy-four patients (80.7 %) recovered completely and discharged without need to icu admission. the response rate was the same in patients with moderate and severe pneumonia. nine cases (4.9 %) were passed away. diabetic patients had higher mortality rates. this study showed the efficacy of ifn-beta1b plus favipiravir in early treatment of patients with moderate to severe covid-19 pneumonia who did need to mechanical ventilation.